Background/Objectives: Calf muscle hypertonicity following stroke may impair walking rehabilitation. The aim of this study was to assess botulinum toxin (Dysport®) in post-stroke calf spasticity. Methods: A prospective, multicentre, double-blind, placebo-controlled, dose-ranging study was performed to evaluate dysport at 500, 1,000 or 1,500 units in 234 stroke patients. They were assessed at 4-week intervals over 12 weeks. Results: The primary outcome measure, 2-min walking distance and stepping rate increased significantly in each group (p < 0.05, paired test), but there was no significant difference between groups (including placebo). Following dysport treatment, there were small but significant (p = 0.0002–0.0188) improvements in calf spasticity, limb pain, and a reduction in the use of walking aids, compared to placebo. Investigators’ and patients’ assessments of overall benefit suggested an advantage for dysport over placebo, but this was not significant. Sixty-eight patients reported 130 adverse events, with similar numbers in each group. The few severe events recorded were not considered to be treatment-related. Conclusion: Dysport resulted in a significant reduction in muscle tone, limb pain and dependence on walking aids. The greatest benefits were in patients receiving dysport 1,500 units, but 1,000 units also had significant effects. Dysport 500 units resulted in some improvements. Since few adverse events were reported, this therapy is considered safe and may be a useful treatment in post-stroke rehabilitation of the leg. Possible reasons why functional improvements in gait parameters were not observed are also discussed.

Keywords:
Botulinum toxin, Calf, Dysport, Equinovarus deformity, Pain, Rehabilitation, Spasticity, Stroke, Walking
1.
Nadeau S, Gravel D, Arsenault AB, Bourbonnais D: Plantarflexor weakness as a limiting factor of gait speed in stroke subjects and the compensating role of hip flexors. Clin Biomech (Bristol, Avon) 1999;14:125–135.
2.
Young RR, Delwaide PJ: Drug therapy: Spasticity. Part 1. New Engl J Med 1981;304:28–33.
3.
Young RR, Delwaide PJ: Drug therapy: Spasticity. Part 2. New Engl J Med 1981;304:96–99.
4.
Katz RT: Management of spasticity. Am J Phys Med Rehabil 1988;67:108–116.
5.
Penn RD, Savoy SM, Corcos D, Latash ML, Gottlieb G: Intrathecal baclofen for severe spinal spasticity. New Engl J Med 1989;320:1517–1521.
6.
Herz DA, Looman JE, Tiberio A, Ketterling K, Kreitsch RK, Colwill JC, Grin OD: The management of paralytic spasticity. Neurosurgery 1990;26:300–306.
7.
Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG: Injection of botulinum A toxin into the gastrocnemius muscle of patients with cerebral palsy: A 3-dimensional motion analysis study. Gait Posture 1996;4:269–279.
8.
Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK: Botulinum toxin A in the hemiplegic upper limb: A double-blind trial. Dev Med Child Neurol 1997;39:185–193.
9.
Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA: Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996;61:30–35.
10.
Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM: Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: A randomised double-blind placebo-controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217–221.
11.
Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, Benecke R, Collin C, Muller F, Ward CD, Neumann C: A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402–2406.
12.
Burbaud P, Wiart L, Dubos JL, Gaujard E, Debelleix X, Joseph P, Mazaux JM, Bioulac B, Barat M, Lagueny A: A randomised, double-blind, placebo-controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996;61:265–269.
13.
Hesse S, Krajnik J, Luecke D, Jahnke MT, Gregoric M, Mauritz KH: Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke 1996;27:455–460.
14.
Simpson DM, Alexander DN, O’Brien CF, Tagliati M, Aswad AS, Leon JM, Gibson J, Mordaunt JM, Monaghan EP: Botulinum toxin type A in the treatment of upper extremity spasticity: A randomised, double-blind, placebo-controlled trial. Neurology 1996;46:1306–1310.
15.
Sheean GL: Botulinum treatment of spasticity: Why is it so difficult to show a functional benefit? Curr Opin Neurol 2001;14:771–776.
16.
Hatano S: Experience from a multicentre stroke register: A preliminary report. Bull World Health Organ 1976;54:541–553.
17.
Butland RJA, Pang J, Gross ER, Woodcock AA, Geddes DM: Two-, six- and 12-minute walking tests in respiratory disease. BMJ 1982;284:1607–1608.
18.
Lincoln N, Leadbitter D: Assessment of motor function in stroke patients. Physiotherapy 1979;65:48–51.
19.
Bohannon RW, Smith MB: Inter-rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206–207.
20.
US Food and Drug Administration: COSTART: Coding Symbols for Thesaurus of Adverse Reaction terms, ed 5. Rockville, 1995.
21.
Mauritz K-H, Hesse S: Neurological rehabilitation of gait and balance disorders; in Bronstein A, et al. (eds): Clinical Disorders of Balance, Posture and Gait. London, Arnold, 1996, pp 236–250.
22.
Dodd SL, Rowell BA, Vrabas IS, Arrowsmith RJ, Weatherill PJ: A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function. Eur J Neurol 1998;5:181–186.
23.
Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ: Botulinum A toxin for the treatment of spasmodic torticollis: Dysphagia and regional toxin spread. Head Neck 1990;12:392–399.
24.
Eleopra R, Tugnoli V, Caniatti L, De Grandis D: Botulinum toxin treatment in the facial muscles of humans: Evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 1996;46:1158–1160.
25.
Geenen C, Consky E, Ashby P: Localizing muscles for botulinum toxin treatment of focal hand dystonia. Can J Neurol Sci 1996;23:194–197.
26.
Ross MH, Charness ME, Sudarsky L, Logigian EL: Treatment of occupational cramp with botulinum toxin: Diffusion of toxin to adjacent non-injected muscles. Muscle Nerve 1997;20:593–598.
27.
Snow BJ, Tsui JKC, Bhatt MH, Varelas M, Hashimoto SA, Calne BD: Treatment of spasticity with botulinum toxin: A double-blind study. Ann Neurol 1990;28:512–515.
28.
Molteni F: Botulinum toxin and rehabilitation programs in lower limb spasticity. Eur J Neurol 1995;2:61–67.
29.
Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H: A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin Rehabil 1999;13:373–383.
30.
Das TK, Park DM: Effect of treatment with botulinum toxin on spasticity. Postgrad Med J 1989;65:208–210.
31.
Dengler R, Neyer U, Wohlfarth K, Bettig U, Janzik HH: Local botulinum toxin in the treatment of spastic foot drop. J Neurol 1992;239:375–378.
32.
Hesse S, Lücke D, Malezic M, Bertelt C, Friedrich H, Gregoric M, Mauritz K-H: Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry 1994;57:1321–1324.
33.
Dunne JW, Heye N, Dunne SL: Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry 1995;58:232–235.
34.
Reiter F, Danni M, Ceravolo MG, Provinciali L: Disability changes after treatment of upper limb spasticity with botulinum toxin. J Neurol Rehabil 1996;10:47–52.
35.
Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M, Topka H, Poewe W: Management of spasticity-associated pain with botulinum toxin. J Pain Symptom Manage 2000;20:44–49.
36.
Rice-Oxley M, Turner-Stokes L: Effectiveness of brain injury rehabilitation. Clin Rehabil 1999;13:7–24.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.